Harmony Biosciences Holdings (HRMY) Research & Development (2019 - 2026)

Harmony Biosciences Holdings has disclosed Research & Development across 8 years of filings, most recently posting $69.4 million for Q1 2026.

• Research & Development for Q1 2026 came in at $69.4 million, up 100.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $189.3 million (up 19.66% YoY), and the FY2025 annual result was $189.6 million, up 30.01% from the prior year.
• Research & Development came in at $69.4 million for Q1 2026 at Harmony Biosciences Holdings, up from $49.9 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $69.4 million in Q1 2026 to a low of $7.6 million in Q1 2022.
• The 5-year median for Research & Development is $25.4 million (2024), against an average of $30.4 million.
• Across the five-year window, Research & Development surged 324.76% in 2024 and slumped 76.41% in 2025, its largest moves.
• Harmony Biosciences Holdings' Research & Development stood at $10.1 million in 2022, then soared by 200.3% to $30.3 million in 2023, then increased by 14.39% to $34.7 million in 2024, then jumped by 44.04% to $49.9 million in 2025, then surged by 38.95% to $69.4 million in 2026.
• The last three Research & Development figures came in at $69.4 million (Q1 2026), $49.9 million (Q4 2025), and $55.0 million (Q3 2025), per Business Quant data.